诚意药业(603811.SH)：盐酸多巴酚丁胺注射液药品通过仿制药一致性评价

Core Viewpoint - Chengyi Pharmaceutical (603811.SH) has received approval from the National Medical Products Administration for its supplemental drug application, indicating that its product, Dobutamine Hydrochloride Injection, has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved product, Dobutamine Hydrochloride Injection, is primarily used for heart failure caused by decreased myocardial contractility in organic heart disease [1] - The drug is also indicated for short-term support treatment in cases of low cardiac output syndrome following cardiac surgery [1]